Provider review
MEDVi tirzepatide review
What MEDVi charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of MEDVi's tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What is distinctive about this programme
Two figures we will not assert
Our source dataset flags MEDVi's $399 tirzepatide rate as not appearing on the current GLP-1 landing page, and its $369 oral semaglutide rate as third-party reporting rather than a direct capture. We have imported both as pending rather than reported, which means they do not appear in any ranking or comparison on this site.
That is the correct handling and it is also the useful information: a price that cannot be found on the provider's own page is not a price a patient can rely on. Verify at intake.
Escalating pricing at higher doses
The tirzepatide programme is reported as a refill rate at lower doses reaching $499 at 10, 12.5 and 15 mg. If accurate, that places it among the most expensive compounded programmes in the market at exactly the doses most patients reach — well above brand Zepbound at $449 direct from LillyDirect.
Introductory rates
The $179 first-month semaglutide rate rises to $299 ongoing, and the $249 first-month oral rate to $369. Both are excluded from our rankings, as all introductory rates are.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $299 | Reported |
| Semaglutide oral / ODT | $369 | Pending |
| Tirzepatide injectable | $399 | Pending |
Where it holds up
- Publishes a refill rate structure rather than a single ambiguous figure
- Semaglutide ongoing pricing is clearly stated
Where it does not
- Tirzepatide pricing could not be found on the current landing page and is marked pending
- Reported escalation to $499 at maintenance doses exceeds brand Zepbound direct
- Introductory first-month rates are substantially below ongoing rates
- Oral semaglutide figure is third-party reported rather than captured
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $299/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| MEDVi | month_to_month | compounded injectable | — | $399 | — | $399 | Recurring | Pending | — |
| MEDVi | month_to_month | compounded injectable | — | $299 | — | $299 | Recurring | Reported | 2026-07-06 |
| MEDVi | month_to_month | compounded oral / ODT | — | $369 | — | $369 | Recurring | Pending | — |
How this sits against the market
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Found | $169 | Reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| NexLife (opens nexlife.us in a new tab) | $190 | Verified |
| NexLife | $195 | Verified |
| NexLife | $215 | Verified |
| Shed | $245 | Reported |
| Mochi Health | $278 | Reported |
| Enhance.MD | $280 | Reported |
| Eden | $298 | Reported |
| Noom Med | $299 | Reported |
| TrimRx | $349 | Reported |
| MEDVi | $399 | Pending |
| bmiMD | $399 | Reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
Pharmacy and fulfilment
Billing, cancellation and support
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where MEDVi sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
Questions readers actually ask
Is MEDVi the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Best Month-to-Month Tirzepatide ProgramsPillar / Money
Related coverage
Tirzepatide Ranked. “MEDVi Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/medvi/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.